Hillmen, P. 2009. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematology Meeting Reports (formerly Haematologica Reports). 1, 2 (May 2009). DOI:https://doi.org/10.4081/hmr.v1i2.226.